close :

:

Forgotten your password?
 
FDA Drug Approvals
Printable Version   Email to a friend

Vectibix Amgen - Treatment for Metastatic Colorectal Cancer

Vectibix is a recombinant, human IgG2 kappa monoclonal antibody indicated for the treatment of patients with epidermal growth factor receptor- (EGFr) expressing metastatic colorectal cancer after disease progression on, or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.

Related Articles:

Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab - March 30, 2006

Latest FDA Drug Approvals...

FDA Drug Approvals Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec

More News Resources